SG11201806214RA - Clinical assessment of m-protein response in multiple myeloma - Google Patents

Clinical assessment of m-protein response in multiple myeloma

Info

Publication number
SG11201806214RA
SG11201806214RA SG11201806214RA SG11201806214RA SG11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA
Authority
SG
Singapore
Prior art keywords
international
pct
clinical assessment
mor202
planegg
Prior art date
Application number
SG11201806214RA
Inventor
Stefan Härtle
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of SG11201806214RA publication Critical patent/SG11201806214RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111010111111111101110111011111101111011111 International Bureau 0.. .... .. (10) International Publication Number ..... ...,/ (43) International Publication Date WO 2017/149122 Al 8 September 2017 (08.09.2017) WIP0 I PCT (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C07K 16/42 (2006.01) GO1N 33/574 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/EP2017/055011 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 3 March 2017 (03.03.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 16158714.2 4 March 2016 (04.03.2016) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: MORPHOSYS AG [DE/DE]; Semmelweisstr. TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 7, 82152 Planegg (DE). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, HARTLE, Stefan; Biberfeldstrasse 3, 82291 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, tor: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventor: rf (DE). Ma n do GW, KM, ML, MR, NE, SN, TD, TG). (74) Agent: HUTTER, Bernd; MORPHOSYS AG, Semmel- weisstr. 7, 82152 Planegg (DE). Published: (81) — with international search report (Art. 21(3)) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, — with sequence listing part of description (Rule 5.2(a)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, = 1-1 ei ei ,-1 (:: ii- ,-1 IN ,-1 © ei (54) Title: CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA C:) ,,,.. (57) : Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti - .,. body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
SG11201806214RA 2016-03-04 2017-03-03 Clinical assessment of m-protein response in multiple myeloma SG11201806214RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16158714 2016-03-04
PCT/EP2017/055011 WO2017149122A1 (en) 2016-03-04 2017-03-03 Clinical assessment of m-protein response in multiple myeloma

Publications (1)

Publication Number Publication Date
SG11201806214RA true SG11201806214RA (en) 2018-08-30

Family

ID=55745535

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806214RA SG11201806214RA (en) 2016-03-04 2017-03-03 Clinical assessment of m-protein response in multiple myeloma

Country Status (10)

Country Link
US (2) US11618789B2 (en)
EP (1) EP3423498A1 (en)
JP (3) JP7362250B2 (en)
KR (1) KR102427948B1 (en)
CN (1) CN108699161B (en)
AU (2) AU2017226960B2 (en)
CA (1) CA3016098A1 (en)
IL (2) IL305540A (en)
SG (1) SG11201806214RA (en)
WO (1) WO2017149122A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209730A1 (en) 2018-04-24 2019-10-31 Helena Laboratories Corporation Removal of interfering factors from serum protein electrophoresis profiles
AU2019338999A1 (en) 2018-09-11 2021-03-18 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use
WO2020187718A1 (en) 2019-03-15 2020-09-24 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
WO2023094696A1 (en) * 2021-11-29 2023-06-01 Morphosys Ag Methods for reducing anti-cd38 mab drug interference in serological assays

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912610A (en) * 1974-07-23 1975-10-14 Icl Scient Method for electroquantitative determination of proteins
US4102990A (en) * 1977-12-05 1978-07-25 General Electric Company Electrophoretic assay for antigen-antibody reaction based on particle-particle coupling
US4661586A (en) 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4578350A (en) * 1983-09-23 1986-03-25 Syntex (U.S.A.) Inc. Immunoassays employing protected labels
US6936464B1 (en) * 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US7348139B1 (en) * 2001-04-13 2008-03-25 The Johns Hopkins University School Of Medicine SOCS-1 gene methylation in cancer
US6902669B2 (en) 2002-09-13 2005-06-07 Fleetguard, Inc. Filter cartridge with floating seal
EP1544215A1 (en) 2003-12-17 2005-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human anti-idiotypic antibody fragments that mimic HER-2/neu
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP1720907B1 (en) 2004-02-06 2015-04-08 MorphoSys AG Anti-cd38 human antibodies and uses therefor
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
EP1888647A2 (en) 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
TWI428444B (en) 2005-10-12 2014-03-01 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
AU2007258609B2 (en) * 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
US20110151494A1 (en) * 2008-06-30 2011-06-23 H. Lee Moffit Cancer & Research Institute Methods and materials for monitoring myeloma using quantitative mass spectrometry
SI2580243T1 (en) 2010-06-09 2020-02-28 Genmab A/S Antibodies against human cd38
RU2595839C2 (en) 2010-09-27 2016-08-27 МорфоСис АГ Anti-cd38 antibody and lenaltdomid or bortezomib for treating multiple myeloma and nhl
EP2621532A1 (en) 2010-09-30 2013-08-07 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her3 antibodies
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
BR112014024291B1 (en) 2012-03-30 2022-07-05 The Board Of Regents Of The University Of Oklahoma METHOD FOR THE RECOMBINANT PRODUCTION OF A HEPAROSAN POLYMER WITH HIGH MOLECULAR WEIGHT, USE OF SUCH TISSUE ANCREASEMENT POLYMER, ISOLATED POLYNUCLEOTIDE AND COMPOSITION OF BIOLOGICAL MATERIAL COMPRISING SUCH POLYMER
CA2885792C (en) 2012-09-25 2021-09-28 Jan Endell Pharmaceutical combination of an anti-cd38 antibody and melphalan for treating multiple myeloma
EA033115B1 (en) 2013-04-29 2019-08-30 Тева Фармасьютикалз Острэйлиа Пти Лтд. Anti-cd38 antibodies and fusion proteins with attenuated interferon alpha-2b
CA2927099A1 (en) 2013-10-31 2015-05-07 Sanofi Specific anti-cd38 antibodies for treating human cancers
US10836998B2 (en) * 2014-02-14 2020-11-17 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells

Also Published As

Publication number Publication date
JP2019513346A (en) 2019-05-30
JP7362250B2 (en) 2023-10-17
IL260750A (en) 2018-09-20
AU2017226960A1 (en) 2018-08-09
US20230203189A1 (en) 2023-06-29
IL260750B1 (en) 2023-10-01
CN108699161B (en) 2022-06-03
IL260750B2 (en) 2024-02-01
WO2017149122A1 (en) 2017-09-08
AU2017226960B2 (en) 2024-03-21
US20190077875A1 (en) 2019-03-14
CA3016098A1 (en) 2017-09-08
IL305540A (en) 2023-10-01
JP2022058881A (en) 2022-04-12
AU2024201503A1 (en) 2024-03-28
KR102427948B1 (en) 2022-08-02
US11618789B2 (en) 2023-04-04
JP7331168B2 (en) 2023-08-22
JP2023157927A (en) 2023-10-26
CN108699161A (en) 2018-10-23
EP3423498A1 (en) 2019-01-09
KR20180118151A (en) 2018-10-30

Similar Documents

Publication Publication Date Title
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201807426WA (en) Immunomodulators
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201810149VA (en) Anti hla-g specific antibodies
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201805001UA (en) Method of treating influenza a
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201806214RA (en) Clinical assessment of m-protein response in multiple myeloma
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof